Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanoma
Tompkins, A.; Gray, Z. N.; Dadey, R. E.; Zenkin, S.; Batavani, N.; Newman, S.; Amouzegar, A.; Ak, M.; Ak, N.; Pak, T. Y.; Peddagangireddy, V.; Mamindla, P.; Behr, S.; Goodman, A.; Ploucha, D. L.; Kirkwood, J. M.; Zarour, H. M.; Najjar, Y. G.; Davar, D.; Colen, R.; Luke, J. J.; Bao, R.
Show abstract
BackgroundVariability in treatment response may be attributable to organ-level heterogeneity in tumor lesions. Radiomic analysis of medical images can elucidate non-invasive biomarkers of clinical outcome. Organ-specific radiomic comparison across immunotherapies and targeted therapies has not been previously reported. MethodsWe queried UPMC Hillman Cancer Center registry for patients with metastatic melanoma (MEL) treated with immune checkpoint inhibitors (ICI) (anti-PD1/CTLA4 [ipilimumab+nivolumab; I+N] or anti-PD1 monotherapy) or BRAF targeted therapy. Best overall response was measured using RECIST v1.1. Lesions were segmented into discrete volume-of-interest with 400 radiomics features extracted. Overall and organ-specific machine-learning models were constructed to predict disease control (DC) versus progressive disease (PD) using XGBoost. Results291 MEL patients were identified, including 242 ICI (91 I+N, 151 PD1) and 49 BRAF. 667 metastases were analyzed, including 541 ICI (236 I+N, 305 PD1) and 126 BRAF. Across cohorts, baseline demographics included 39-47% female, 24-29% M1C, 24-46% M1D, and 61-80% with elevated LDH. Among patients experiencing DC, the organs with the greatest reduction were liver (-88%{+/-}12%, I+N; mean{+/-}S.E.M.) and lung (-72%{+/-}8%, I+N). For patients with multiple same-organ target lesions, the highest inter-lesion heterogeneity was observed in brain among patients who received ICI while no intra-organ heterogeneity was observed in BRAF. 267 patients were kept for radiomic modeling, including 221 ICI (86 I+N, 135 PD1) and 46 BRAF. Models consisting of optimized radiomic signatures classified DC/PD across I+N (AUC=0.85) and PD1 (0.71) and within individual organ sites (AUC=0.72[~]0.94). Integration of clinical variables improved the models performance. Comparison of models between treatments and across organ sites suggested mostly non-overlapping DC or PD features. Skewness, kurtosis, and informational measure of correlation (IMC) were among the radiomic features shared between overall response models. Kurtosis and IMC were also utilized by multiple organ-site models. ConclusionsDifferential organ-specific response was observed across BRAF and ICI with within organ heterogeneity observed for ICI but not for BRAF. Radiomic features of organ-specific response demonstrated little overlap. Integrating clinical factors with radiomics improves the prediction of disease course outcome and prediction of tumor heterogeneity.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma 95%
- Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early- and late-phase clinical trials 94%
- Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies 94%
Similar papers in this journal
- Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors 95%
- Integration of clinical, pathological, radiological, and transcriptomic data improves the prediction of first-line immunotherapy outcome in metastatic non-small cell lung cancer 95%
- Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers 95%
Similar papers in this journal
- Predicting the Tumor Microenvironment Composition and Immunotherapy Response in Non-Small Cell Lung Cancer from Digital Histopathology Images 95%
- Single-Cell Spatial Proteomics Analyses of Head and Neck Squamous Cell Carcinoma Reveal Tumor Heterogeneity and Immune Architectures Associated with Clinical Outcome 94%
- Explainable, federated deep learning model predicts disease progression risk of cutaneous squamous cell carcinoma 93%
Similar papers in this journal
- Tumor-educated Gr1+CD11b+ cells instigate breast cancer metastasis by twisting cancer cells plasticity via OSM/IL6-JAK signaling 93%
- The MNK1/2-eIF4E axis contributes to phenotype switching, melanoma progression, and resistance to immunotherapy. 93%
- Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer 92%
Similar papers in this journal
- An Omic and Multidimensional Spatial Atlas from Serial Biopsies of an Evolving Metastatic Breast Cancer 95%
- Determination of permissive and restraining cancer-associated fibroblast (DeCAF) subtypes 95%
- Conserved angio-immune subtypes of the cancer microenvironment predict response to immune checkpoint blockade therapy 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.